Breaking News

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
HOLX Hologic $39.82 -0.5 (-1.24%) , ILMN Illumina $307.95 -3.29 (-1.06%) … 08:37 11/15/18 11/15 08:37 11/15/18 08:37 Conference/Events	Deutsche Bank to hold a conference » 2018 Medtools &… 2018 Medtools & Diagnostics 1:1 Day will be held in New York on November 15. HOLX Hologic $39.82 -0.5 (-1.24%) ILMN Illumina $307.95 -3.29 (-1.06%) LMNX Luminex $25.94 -0.4 (-1.52%) MTD Mettler-Toledo $581.07 -8.265 (-1.40%) NEO NeoGenomics $16.01 -0.51 (-3.09%) NMRD Nemaura Medical $1.70 -0.08 (-4.49%) QGEN Qiagen $34.22 -0.655 (-1.88%) RGEN Repligen $63.74 -1.65 (-2.52%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	15 Nov 16 Nov 27 Nov 03 Dec 04 Dec
RGEN Repligen $67.74 -1.16 (-1.68%) 08:24 11/12/18 11/12 08:24 11/12/18 08:24 Downgrade	Repligen rating change at CL King » Repligen downgraded to… Repligen downgraded to Neutral from Buy at CL King. CL King analyst David Westenberg downgraded Repligen to Neutral from Buy. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	15 Nov

Over a month ago
POOL Pool Corp. $147.12 0.85 (0.58%) , TACT Transact Technologies $15.09 0.11 (0.73%) … 08:17 11/07/18 11/07 08:17 11/07/18 08:17 Conference/Events	Stephens to hold a conference » Stephens New York… Stephens New York Investment Conference will be held in New York on November 6-8 with webcasted company presentations to begin on November 7 at 8:15 am; not all company presentations may be webcasted. Webcast Link POOL Pool Corp. $147.12 0.85 (0.58%) TACT Transact Technologies $15.09 0.11 (0.73%) FIS FIS $104.68 0.64 (0.62%) FAF First American $45.46 0.63 (1.41%) RAMP LiveRamp $45.85 -0.29 (-0.63%) TECH Bio-Techne $172.32 2.05 (1.20%) ARCB ArcBest $41.08 -0.17 (-0.41%) SAFM Sanderson Farms $104.21 0.63 (0.61%) MRTN Marten Transport $19.83 0.09 (0.46%) RGEN Repligen $67.92 0.65 (0.97%) SUM Summit Materials $14.02 -0.45 (-3.11%) IRIX Iridex $5.40 -0.14 (-2.53%) SIEN Sientra $21.41 -0.1 (-0.46%) QNST QuinStreet $16.53 -0.75 (-4.34%) BLD TopBuild $51.94 2.53 (5.12%) RP RealPage $51.61 -1.3 (-2.46%) LAD Lithia Motors $85.59 -1.46 (-1.68%) R Ryder $56.62 -0.32 (-0.56%) CVTI Covenant Transportation $25.68 0.46 (1.82%) HABT Habit Restaurants $15.83 0.73 (4.83%) LGND Ligand $160.20 0.86 (0.54%) CSU Capital Senior Living $9.33 -0.21 (-2.20%) BIOS BioScrip $3.22 0.41 (14.59%) JKHY Jack Henry $150.88 1.24 (0.83%) RLGY Realogy $18.39 0.18 (0.99%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Nov 07 Nov 08 Nov 08 Nov 08 Nov 08 Nov 12 Nov 13 Nov 13 Nov 13 Nov 15 Nov 15 Nov 15 Nov 26 Nov 03 Dec 10 Dec 13 Dec
RGEN Repligen $66.35 2.79 (4.39%) 07:44 11/05/18 11/05 07:44 11/05/18 07:44 Recommendations	Repligen analyst commentary at H.C. Wainwright » Repligen price target… Repligen price target raised to $60 from $49 at H.C. Wainwright. H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Repligen to $60 but reiterates a Neutral rating on the name. Solid execution produced a "modest beat" in Q3, but the stock reaction may have been overdone, Selvaraju tells investors in a research note. He believes the stock "still looks expensive." 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	06 Nov 15 Nov
RGEN Repligen $54.24 -0.32 (-0.59%) 07:42 11/01/18 11/01 07:42 11/01/18 07:42 Earnings	Repligen raises FY18 EPS view to 71c-75c from 69c-73c, consensus 71c » Raises FY18 revenue view… Raises FY18 revenue view to $191M-$194M from $185M-$190M, consensus $187.92M. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	01 Nov 06 Nov 15 Nov

RGEN Repligen $54.24 -0.32 (-0.59%) 07:40 11/01/18 11/01 07:40 11/01/18 07:40 Earnings	Repligen reports Q3 adj. EPS 20c, consensus 18c » Reports Q3 revenue… Reports Q3 revenue $49.5M, consensus $46.74M. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	01 Nov 06 Nov 15 Nov
FCFS First Cash Financial $84.25 1.225 (1.48%) , TWNK Hostess Brands $11.42 (0.00%) … 10:37 09/26/18 09/26 10:37 09/26/18 10:37 Initiation	On The Fly: Top five analyst initiations » Catch up on today's… Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. First Cash Financial (FCFS) initiated with an Overweight at Barclays. 2. Hostess Brands (TWNK) initiated with a Neutral at Citi. 3. Repligen (RGEN) initiated with a Neutral at H.C. Wainwright. 4. Evofem (EVFM) initiated with an Overweight at Cantor Fitzgerald. 5. Elanco (ELAN) initiated with a Market Perform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here. FCFS First Cash Financial $84.25 1.225 (1.48%) TWNK Hostess Brands $11.42 (0.00%) RGEN Repligen $54.10 -0.25 (-0.46%) EVFM Evofem $4.33 0.1 (2.36%) ELAN Elanco $34.89 0.24 (0.69%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	26 Sep 26 Sep 01 Oct 30 Oct 06 Nov 06 Nov
RGEN Repligen $54.35 -0.71 (-1.29%) 07:08 09/26/18 09/26 07:08 09/26/18 07:08 Initiation	Repligen initiated at H.C. Wainwright » Repligen initiated with a… Repligen initiated with a Neutral at H.C. Wainwright. H.C. Wainwright analyst Raghuram Selvaraju started Repligen with a Neutral rating and $49 price target. The analyst views the shares as "pricey" at current levels, but would view the stock as attractive into the low $40s. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	06 Nov
RGEN Repligen $55.16 -1.67 (-2.94%) 07:16 09/24/18 09/24 07:16 09/24/18 07:16 Recommendations	Repligen analyst commentary at JPMorgan » Repligen price target… Repligen price target raised to $60 from $55 at JPMorgan. JPMorgan analyst Tycho Peterson raised his price target for Repligen to $60 following meetings with management. The analyst came away with reinforced confidence in the company's "strategic direction, strong competitive positioning, and sustainable growth momentum." He remains positive on the long-term outlook of the bioprocessing market and keeps an Overweight rating on Repligen shares. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	06 Nov
RGEN Repligen $57.68 0.24 (0.42%) 04:55 09/20/18 09/20 04:55 09/20/18 04:55 Conference/Events	Repligen management to meet with JPMorgan » Meeting to be held in… Meeting to be held in Atlanta on September 20 hosted by JPMorgan. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	20 Sep 06 Nov

On The Fly

News and insights, exclusive to thefly.com

19:00	Fly Intel: After Hours Movers»
15:39	Farfetch rises after agreeing to acquire Stadium Goods in $250M deal»
12:39	Notable companies reporting before tomorrow's open»
12:38	Notable companies reporting after market close»
11:27	j2 Global mentioned cautiously in new GlassHouse Research short report»

View all On The Fly Stories »

Upcoming
Events (10)

	E&C Bus Tour
MGNX	12th Annual Leerink POLARxPRESS Conference
	37th Annual SEC Government-Business Forum on Small Business Capital Formation
	Maxim Group TMT Conference 2018
MNK ...	2018 Prescriptions for Success Healthcare Conference
SOLO	Emerging Growth Invitational
APTO	Novel Treatment for AML and B-cell Cancers
EXPI ...	2018 Seattle Field Trip
	Reinsurance/Specialty Insurance 1:1 Conference
	5th Annual Network & Cybersecurity Summit

View all of today’s events »

Today’s
Syndicate (8)

PVTL	Block Trade
TME	IPO
RARX	Secondary
ANGI	Spot Secondary
FLDM	Spot Secondary
GMRE	Spot Secondary
LAND	Spot Secondary
NEO	Spot Secondary

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial